Floatz Rating
B57/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01266447CT.gov Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cervical Small Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | National Cancer Institute (NCI) | P2 | B · 57 |
| Cis-Diamminedichloroplatinum Ii | Uganda Cancer Institute | P2 | BB |
| Pegfilgrastim | National Cancer Institute (NCI) | P2 | B |
| Veliparib | National Cancer Institute (NCI) | P2 | B |
| Nogitecan | National Cancer Institute (NCI) | P2 | B |
| Ferumoxtran 10 | National Cancer Institute (NCI) | P1/2 | CCC |
| 1-(4,4-BIS(P-FLUOROPHENYL)BUTYL)-4-(4-CHLORO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)-4-PIPERIDINOL | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | P1/2 | CCC |
| Cetuximab | Gynecologic Oncology Group | P1 | CC |
| Axalimogene Filolisbac | Advaxis, Inc. | P1 | CC |
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in Cervical Small Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-cervical-small-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →